Request Demo
Last update 08 May 2025
SCTB-14
Last update 08 May 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with SCTB-14CTR20250935
一项评估SCTB14联合培美曲塞和顺铂/卡铂对比安慰剂联合培美曲塞和顺铂/卡铂用于经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗失败的EGFR突变的局部晚期或转移性非鳞非小细胞肺癌患者的II/III期临床研究
[Translation] A phase II/III clinical study evaluating SCTB14 combined with pemetrexed and cisplatin/carboplatin versus placebo combined with pemetrexed and cisplatin/carboplatin in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who have failed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy
CTR20241479
一项评估SCTB14用于治疗晚期恶性实体瘤患者的安全耐受性、药代动力学和抗肿瘤活性的开放、多中心、剂量递增和剂量扩展
的I/Ⅱ期临床试验
[Translation] An open, multicenter, dose-escalation and dose-expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of SCTB14 in the treatment of patients with advanced malignant solid tumors
NCT06304818
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours
100 Clinical Results associated with SCTB-14
Login to view more data
100 Translational Medicine associated with SCTB-14
Login to view more data
100 Patents (Medical) associated with SCTB-14
Login to view more data
100 Deals associated with SCTB-14
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR positive Non-squamous non-small cell lung cancer | Phase 3 | China | 25 Mar 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | - | 30 Apr 2024 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | IND Approval | China | 10 Mar 2025 | |
| metastatic non-small cell lung cancer | IND Approval | China | 10 Mar 2025 | |
| EGFR-mutated non-small Cell Lung Cancer | IND Approval | China | 10 Mar 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free